Table 2.
Immune-Related Adverse Events
| Patient Characteristics and Treatment | 2-Weekly (n = 150) |
4-Weekly (n = 52) |
||
|---|---|---|---|---|
| All Grades | Grade ≥3 | All Grades | Grade ≥3 | |
| Any | 88 (58.7) | 19 (12.7) | 29 (55.8) | 6 (11.5) |
| Skin | 18 (12.0) | 0 | 7 (13.5) | 0 |
| Endocrine | 28 (18.7) | 2 (1.3) | 7 (13.5) | 0 |
| Lung | 15 (10.0) | 5 (3.3) | 6 (11.5) | 3 (5.8) |
| Lung, mixeda | 13 (8.7) | 6 (4.0) | 2 (3.8) | 0 |
| Gastrointestinal | 22 (14.7) | 6 (4.0) | 5 (9.6) | 2 (3.8) |
| Rheumatologic | 17 (11.3) | 1 (0.7) | 7 (13.5) | 0 |
| Otherb | 7 (4.7) | 1 (0.7) | 5 (9.6) | 1 (2.9) |
| Durvalumab treatment held at least once (p = 0.75) | 39 (25.7) | 12 (22.6) | ||
| Durvalumab treatment stopped because of toxicity (p = 0.68) | 33 (22.0) | 13 (25) | ||
| Clinically relevant toxicityc (p = 0.56) | 51 (34.0) | 20 (38.5) | ||
Note: Data are presented as n (%).
a
Unclear or mixed cause between radiation and durvalumab.
b
Cardiovascular, neurologic, hematologic.
c
Defined as toxicity that caused a missed dose, treatment cessation, or hospital admission.